Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 418

1.

B-cell signaling in persistent polyclonal B lymphocytosis (PPBL).

Voelxen N, Wehr C, Gutenberger S, Keller B, Erlacher M, Dominguez-Conde C, Bertele D, Emmerich F, Pantic M, Jennings S, Rakhmanov M, Foerster C, Martens UM, Platzbecker U, Peter HH, Fisch P, Boztug K, Eibel H, Salzer U, Warnatz K.

Immunol Cell Biol. 2016 May 31. doi: 10.1038/icb.2016.46. [Epub ahead of print]

PMID:
27126628
2.

Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.

Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Peichl P, Pavelka K, Chartier M, Poncet C, Rauch C, Le Bars M.

Clin Exp Rheumatol. 2016 May-Jun;34(3):489-99. Epub 2016 Mar 10.

PMID:
26966919
3.

Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study.

Alten R, Nüßlein H, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Elbez Y, Le Bars M.

RMD Open. 2016 Feb 15;2(1):e000228. doi: 10.1136/rmdopen-2015-000228. eCollection 2016.

4.

The crossroads of autoimmunity and immunodeficiency: Lessons from polygenic traits and monogenic defects.

Grimbacher B, Warnatz K, Yong PF, Korganow AS, Peter HH.

J Allergy Clin Immunol. 2016 Jan;137(1):3-17; quiz 18. doi: 10.1016/j.jaci.2015.11.004. Review.

PMID:
26768758
5.

Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.

Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Le Bars M.

BMC Musculoskelet Disord. 2015 Jul 30;16:176. doi: 10.1186/s12891-015-0636-9.

6.

[Heterozygote forms of familial Mediterranean fever can be manifested in adults as myofacial pain syndrome].

Meilinger A, Burger M, Peter HH.

Z Rheumatol. 2015 Aug;74(6):533-9. doi: 10.1007/s00393-014-1518-5. German.

PMID:
25604326
7.

Analysis of specific IgG titers against tick-borne encephalitis in patients with primary antibody deficiency under immunoglobulin substitution therapy: impact of plasma donor origin.

Goldacker S, Witte T, Huzly D, Schlesier M, Peter HH, Warnatz K.

Front Immunol. 2015 Jan 5;5:675. doi: 10.3389/fimmu.2014.00675. eCollection 2014.

8.

Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency.

Wehr C, Gennery AR, Lindemans C, Schulz A, Hoenig M, Marks R, Recher M, Gruhn B, Holbro A, Heijnen I, Meyer D, Grigoleit G, Einsele H, Baumann U, Witte T, Sykora KW, Goldacker S, Regairaz L, Aksoylar S, Ardeniz Ö, Zecca M, Zdziarski P, Meyts I, Matthes-Martin S, Imai K, Kamae C, Fielding A, Seneviratne S, Mahlaoui N, Slatter MA, Güngör T, Arkwright PD, van Montfrans J, Sullivan KE, Grimbacher B, Cant A, Peter HH, Finke J, Gaspar HB, Warnatz K, Rizzi M; Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation and the European Society for Immunodeficiency.

J Allergy Clin Immunol. 2015 Apr;135(4):988-97.e6. doi: 10.1016/j.jaci.2014.11.029. Epub 2015 Jan 14.

PMID:
25595268
9.

Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe.

Kerr J, Quinti I, Eibl M, Chapel H, Späth PJ, Sewell WA, Salama A, van Schaik IN, Kuijpers TW, Peter HH.

Front Immunol. 2014 Dec 12;5:629. doi: 10.3389/fimmu.2014.00629. eCollection 2014. Review.

10.

Evaluation of a questionnaire to assess selected infectious diseases and their risk factors : findings of a multicenter study.

Sievers C, Akmatov MK, Kreienbrock L, Hille K, Ahrens W, Günther K, Flesch-Janys D, Obi N, Michels KB, Fricke J, Greiser KH, Kaaks R, Peter HH, Pessler F, Nieters A, Krause G.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Nov;57(11):1283-91. doi: 10.1007/s00103-014-2052-y.

11.

European consensus proposal for immunoglobulin therapies.

Sewell WA, Kerr J, Behr-Gross ME, Peter HH; Kreuth Ig Working Group.

Eur J Immunol. 2014 Aug;44(8):2207-14. doi: 10.1002/eji.201444700.

12.

High levels of SOX5 decrease proliferative capacity of human B cells, but permit plasmablast differentiation.

Rakhmanov M, Sic H, Kienzler AK, Fischer B, Rizzi M, Seidl M, Melkaoui K, Unger S, Moehle L, Schmit NE, Deshmukh SD, Ayata CK, Schuh W, Zhang Z, Cosset FL, Verhoeyen E, Peter HH, Voll RE, Salzer U, Eibel H, Warnatz K.

PLoS One. 2014 Jun 19;9(6):e100328. doi: 10.1371/journal.pone.0100328. eCollection 2014.

13.

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.

Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Rainer F, Pavelka K, Chartier M, Poncet C, Rauch C, Bars ML.

BMC Musculoskelet Disord. 2014 Jan 11;15:14. doi: 10.1186/1471-2474-15-14.

14.

B cell homeostasis is disturbed by immunosuppressive therapies in patients with ANCA-associated vasculitides.

Thiel J, Salzer U, Hässler F, Effelsberg NM, Hentze C, Sic H, Bartsch M, Miehle N, Peter HH, Warnatz K, Schlesier M, Voll RE, Venhoff N.

Autoimmunity. 2013 Nov;46(7):429-38. doi: 10.3109/08916934.2013.798652. Epub 2013 Jun 6.

PMID:
23742274
15.

Adult-onset immunodeficiency--why is it important in rheumatology?

Peter HH.

Arthritis Res Ther. 2013 Jan 30;15(1):105. doi: 10.1186/ar4121. No abstract available.

16.

[Interdisciplinary AWMF guideline for the treatment of primary antibody deficiencies].

Krudewig J, Baumann U, Bernuth von H, Borte M, Burkhard-Meier U, Dueckers G, Foerster-Waldl E, Franke K, Habermehl P, Hönig M, Kern W, Kösters K, Kugel K, Lehrnbecher T, Liese J, Marks R, Müller GA, Müller R, Nadal D, Peter HH, Pfeiffer-Kascha D, Schneider M, Sitter H, Späth P, Wahn V, Welte T, Niehues T; Arbeitsgemeinschaft Pädiatrische Immunologie e. V. (API).

Klin Padiatr. 2012 Oct;224(6):404-15. doi: 10.1055/s-0032-1323837. Epub 2012 Nov 9. German.

PMID:
23143768
17.

[How I treat …].

Moosig F, Reinhold-Keller E, Holl-Ulrich K, Feller AC, Bley T, Holle JU, Zwerina J, Lamprecht P, Dalhoff K, Venhoff N, Thiel J, Peter HH, Laudien M, Quetz J, Ambrosch P, Both M, Heller M.

Z Rheumatol. 2012 Nov;71(9):775-84. doi: 10.1007/s00393-012-0988-6. German. No abstract available.

PMID:
23138555
18.

[Is the art of being a physician still current?].

Peter HH.

Z Rheumatol. 2012 Nov;71(9):732-41. doi: 10.1007/s00393-012-1057-x. German. No abstract available.

PMID:
23076595
19.

Common variable immunodeficiency: an update.

Salzer U, Warnatz K, Peter HH.

Arthritis Res Ther. 2012 Sep 24;14(5):223. doi: 10.1186/ar4032. Review.

20.

Elevated serum osteopontin levels in idiopathic retroperitoneal fibrosis.

Binder M, Christoph S, Sehnert B, Uhl M, Peter HH, Voll RE, Warnatz K, Kollert F.

Clin Exp Rheumatol. 2012 Sep-Oct;30(5):772-5. Epub 2012 Oct 17.

PMID:
22935225
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk